Fatty acid binding protein 5 is a novel therapeutic target for hepatocellular carcinoma

BACKGROUND Hepatocellular carcinoma(HCC)is an aggressive subtype of liver cancer and is one of the most common cancers with high mortality worldwide.Reprogrammed lipid metabolism plays crucial roles in HCC cancer cell survival,growth,and evolution.Emerging evidence suggests the importance of fatty acid binding proteins(FABPs)in contribution to cancer progression and metastasis;however,how these FABPs are dysregulated in cancer cells,especially in HCC,and the roles of FABPs in cancer progression have not been well defined.AIM To understand the genetic alterations and expression of FABPs and their associated cancer hallmarks and oncogenes in contributing to cancer malignancies.METHODS We used The Cancer Genome Atlas datasets of pan cancer and liver hepatocellular carcinoma(LIHC)as well as patient cohorts with other cancer types in this study.We investigated genetic alterations of FABPs in various cancer types.mRNA expression was used to determine if FABPs are abnormally expressed in tumor tissues compared to non-tumor controls and to investigate whether their expression correlates with patient clinical outcome,enriched cancer hallmarks and oncogenes previously reported for patients with HCC.We determined the protein levels of FABP5 and its correlated genes in two HCC cell lines and assessed the potential of FABP5 inhibition in treating HCC cells.RESULTS We discovered that a gene cluster including five FABP family members(FABP4,FABP5,FABP8,FABP9 and FABP12)is frequently co-amplified in cancer.Amplification,in fact,is the most common genetic alteration for FABPs,leading to overexpression of FABPs.FABP5 showed the greatest differential mRNA expression comparing tumor with non-tumor tissues.High FABP5 expression correlates well with worse patient outcomes(P<0.05).FABP5 expression highly correlates with enrichment of G2M checkpoint(r=0.33,P=1.1e-10),TP53 signaling pathway(r=0.22,P=1.7e-5)and many genes in the gene sets such as CDK1(r=0.56,P=0),CDK4(r=0.49,P=0),and TP53(r=0.22,P=1.6e-5).Furthermore,FABP5 also correlates well with two co-expressed oncogenes PLK1 and BIRC5 in pan cancer especially in LIHC patients(r=0.58,P=0;r=0.58,P=0;respectively).FABP5high Huh7 cells also expressed higher protein levels of p53,BIRC5,CDK1,CDK2,and CDK4 than FABP5low HepG2 cells.FABP5 inhibition more potently inhibited the tumor cell growth in Huh7 cells than in HepG2 cells.CONCLUSION We discovered that FABP5 gene is frequently amplified in cancer,especially in HCC,leading to its significant elevated expression in HCC.Its high expression correlates well with worse patient outcome,enriched cancer hallmarks and oncogenes in HCC.FABP5 inhibition impaired the cell viability of FABP5high Huh7 cells.All these support that FABP5 is a novel therapeutic target for treating FABP5high HCC.

Platycodon grandiflorum extract represses up-regulated adipocyte fatty acid binding protein triggered by a high fat feeding in obese rats

AIM: To investigate the effect of Platycodon grandi- florum extract (PGE) on lipid metabolism and FABP mRNA expression in subcutaneous adipose tissue of high fat diet-induced obese rats. METHODS: PGE was treated to investigate the inhibitory effect on the pre-adipocyte 3T3-L1 differentiation and pancreatic lipase activity. Male Sprague-Dawley rats with an average weight of 439.03 ± 7.61 g were divided into four groups: the control groups that fed an experimental diet alone (C and H group) and PGE treatment groups that administered PGE along with a control diet or HFD at a concentration of 150 mg/kg body weight (C + PGE and H + PGE group, respectively) for 7 wk. Plasma total cholesterol (TC) and triglycerol (TG) concentrations were measured from the tail vein of rats. Adipocyte cell area was measured from subcutaneous adipose tissue and the fatty acid binding protein (FABP) mRNA expression was analyzed by northern blot analysis. RESULTS: PGE treatment inhibited 3T3-L1 pre-adipocyte differentiation and fat accumulation, and also decreased pancreatic lipase activity. In this experiment, PGE signifi cantly reduced plasma TC and TG concentrations as well as body weight and subcutaneous adipose tissue weight. PGE also significantly decreased the size of subcutaneous adipocytes. Furthermore, it significantly repressed the up-regulation of FABP mRNA expression induced by a high-fat feeding in subcutaneous adipose tissue. CONCLUSION: PGE has a plasma lipid lowering-effect and anti-obesity effect in obese rats fed a high fat diet.From these results, we can suggest the possibility that PGE can be used as a food ingredient or drug component to therapeutically control obesity.

Role of Heart-Type Fatty Acid Binding Protein in Early Detection of Acute Myocardial Infarction in Comparison with cTnI, CK-MB and Myoglobin

Heart fatty acid-binding protein (H-FABP) is supposed to be the most sensitive biomarker of early acute myocardial infarction (AMI). To evaluate the diagnostic value of H-FABP for AMI in the early stage, the plasma levels of H-FABP were measured by sandwich ELISA in 93 patients with suspected AMI at admission within 6 h after onset of chest pain and 69 normal healthy subjects. The plasma concentrations of cardiac troponin-I (cTnI), creatine kinase-MB (CK-MB) and myoglobin (Mb) were assayed at the same time by using corpuscle chemiluminescence for those patients. The patients were classified as AMI group (n=32) and non-AMI group (n=61) retrospectively. The diagnostic validity was evaluated in terms of sensitivity, specificity and receiver operating characteristic (ROC) curve analysis. The results showed the cutoff value of H-FABP for AMI was 16.8 ng/ml, and its diagnostic sensitivity for AMI was 64.29 % within 3 h and 84.38 % within 6 h after onset of chest pain, and the diagnostic specificity for non-AMI was 100 % within 3 h and 91.8 % within 6 h. H-FABP had higher sensitivity than that of cTnI and CK-MB at all time points (P<0.05), whereas there was no significant difference in specificity among the four markers. But the area under the ROC curve of H-FABP was significantly greater than that of cTnI, CK-MB and Mb within 3 h. These results revealed that H-FABP possessed high diagnostic sensitivity and specificity for AMI in early stage, especially within 3 h after onset of persistent angina pectoris. In conclusion, H-FABP can be used as a sensitive marker for AMI in the early stage.

THE ASSOCIATION OF Ala54Thr VARIANT OF INTESTINAL FATTY ACID BINDING PROTEIN GENE WITH GENERAL AND REGIONAL ADIPOSE TISSUE DEPOTS

Objective. To ascertain the relationship between the Ala54Thr variation of FABP2 gene and general as well as regional adipose tissue depots. Subjects. 165 subjects, in which 86 were subjects with normal glucose tolerance (NGT) [age 54 45±9 80, male/female 1 05,body mass index (BMI)26 48±4 01] and 79 were subjects with non insulin dependent diabetes mellitus (NIDDM)(age 55 86±10 00,male/female 1 08,BMI 26 75±3 30). Design and measurements. An association study of FABP2 Ala54Thr variation detected by PCR/HhaI digestion with general and regional adipose tissue depots determined by BMI and magnetic resonance imaging [abdominal subcutaneous and visceral adipose tissue area (SA and VA) and femoral subcutaneous adipose tissue area (FA)]. Results. The geneotype and allele frequencies of FABP2 Ala54Thr variation in Chinese were quite close to the frequencies in American Caucasians and Pima Indians reported in the literature. Significant difference in genotype frequency distribution was observed between FA subgroups comparisons (FA≥75cm 2 versus FA<75cm 2 )in NIDDM subjects (X 2 =11 460,P=0 003),with significantly increased in Thr54 carrier[Thr54(+)]genotype frequency and Thr54 allele frequency in NIDDM subject with FA<75cm 2 (odd ratio for genotype was 4 62,X 2 =10 112,P=0 001;and for allele=2 36,X 2 =5 379,P=0 020).The FA in NIDDM Thr54(+)subgroup was significantly lower than that in subjects with NIDDM Thr54( )sugroup(61 19±21 51cm 2 versus 75 36±31 70cm 2 ,P=0 021). Stepwise regression analysis revealed that FABP2 Thr54 genotype variation was an independent factor contributing to the variation of FA in NIDDM(P=0 003). Conclusion. FABP2 is associated with regional adipose tissue depot.The decreased femoral subcutaneous adipose tissue depot in NIDDM subjects is related to FABP2 Thr54 variant.

Expression and Characterization of Human Heart Type Fatty Acid Binding Protein in Pichia Pastoris

H-FABP is regarded as a tissue-specific protein existing only in myocardial cells. It is released from the cardiac tissue and gets into the plasma when a heart attack occurs; the myocardial infarction is a good case in point. As a resuit, the detection of H-FABP will be an early and important biomarker for the disease concerned. The objective of the study is to prepare the recombinant H-FABP by aeukaryotic expression system, pichia, to produce the protein mimicking natural H-FABP, as an immunogen for the production of the specific antibody. A gene fragment encoding H-FABP was cloned in the expressing vector pPICZα, after sequencing. The recombinant plasmid was transformed into the competent cells of the X-33 strain by means of electroporation. The expression of the target peptide induced by methanol was screened by means of Western hlotting, with the available MAb（Clone 6B6）. Highly expressive engineer strains were obtained. The production of recombinant H-FABP under induction was about 0.7 g/L, with an Mr of 14.5 kDa and recognized by a commercially available MAb （Clone 6B6）. The recombinant vector was successfully constructed. Following this, H-FABP was expressed in X-33, and it would become the source of the preparation of specific antibodies, to develop diagnostic kits.

Correlation study of serum epithelial fatty acid binding protein with glucose and lipid metabolism and micro inflammatory reaction in obese children

Objective: To study the correlation of serum epithelial fatty acid binding protein (E-FABP) with glucose and lipid metabolism and micro inflammatory reaction in obese children. Methods: children diagnosed as simple obesity in endocrinology department of my hospital during June 2014 – August 2017 were selected as the obese group, and the health examination children were selected as the control group. The serum was collected and the levels of E-FABP, glucose and lipid metabolism and inflammatory cytokines were determined, peripheral blood was collected and the expression level of insulin signal molecules were measured. Results:serum E-FABP content of obese group was significantly higher than that in the control group;serum total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), Leptin, Chemerin, F-INS, tumor necrosis factor - α (TNF-α), interleukin -1β (IL-β), interleukin-6 (IL-6), soluble intercellular adhesion molecule -1 (sICAM-1) and monocyte chemoattractant protein 1 (MCP1) of obese group were significantly higher than thosein the control group and positively correlated with serum E-FABP content;serum high density lipoprotein cholesterol (HDL-C), lipoprotein (APN), and C1q/tumor necrosis factor-related proteins 12 (CTRP12), Omentin-1 and the expression intensity of insulin receptor substrate 1 (IRS1), IRS2, glucose transporter -4 (GLUT-4) in peripheral blood were significantly lower than those of the control group and negatively correlated with serum E-FABP content. Conclusion: the excessive secretion of E-FABP in obese children is closely related to the disorder of glucose and lipid metabolism and the activation of micro inflammatory reaction.

Sequencing of Intron 3 of Porcine Heart Fatty Acid-Binding Protein Gene

[ Objective] The aim of this paper is to provide the basic data for marker-assisted selection of pig breeding using porcine heart fatty acid- binding protein （H-FABP） gene. [Method] According to the related sequences of porcine H-FABP gene released in GenBank, specific primers were designed to amplify the intron 3 of porcine H-FABP gene. [ Result] The intron 3 of porcine H-FABP gene was amplified successfully. Its whole sequence was 1 350 bp in length and had been submitted to GenBank （Accession no. ： DQ 002993）. [Condusion] The study lays a theoretical foundation for determination of the major genes affecting intramuscular fat deposition.

H-FABP、NT-proBNP与急性心力衰竭患者容量负荷状态及预后的相关性

目的 研究心型脂肪酸结合蛋白(H-FABP)、氨基端脑钠肽前体(NT-proBNP)对急性心力衰竭患者容量负荷状态及预后的评估。方法 本研究为前瞻性研究,以2021年1月至2022年1月于安阳市人民医院急诊住院的老年急性心力衰竭患者83例作为研究组,另选取83例健康者作为对照组。根据相对容量平衡水平,将以上83例患者分为容量超负荷组和非容量超负荷组,对所有出院患者随访3个月,将发生死亡的患者归为死亡组,其余为生存组。比较研究组与对照组不同容量负荷、不同预后的H-FABP、NT-proBNP水平之间的差异,研究H-FABP、NT-proBNP与生存状况以及容量负荷状态的相关性。结果 研究组患者的H-FABP、NT-proBNP水平高于对照组(P<0.001);容量超负荷组患者的H-FABP、NT-proBNP水平高于非容量超负荷组(P<0.05);死亡组患者的H-FABP、NT-proBNP水平高于生存组(P<0.05)。通过相关性分析,患者的死亡以及容量超负荷与H-FABP、NT-proBNP呈现正相关(P<0.001)。结论 H-FABP、NT-proBNP与急性心力衰竭患者容量负荷状态及预后呈现相关性,有助于评估急性心力衰竭的严重程度,对预后不良患者起到积极的指导治疗作用。

2型糖尿病合并代谢综合征患者血清CTRP9、A-FABP水平变化及临床意义

目的研究2型糖尿病(T2DM)合并代谢综合征(MS)(T2DM~MS)患者血清补体C1q肿瘤坏死因子相关蛋白(CTRP9)、脂肪型脂肪酸结合蛋白(A-FABP)水平变化及临床意义。方法前瞻性选择2021年1月至2023年12月于广西医科大学第二附属医院治疗的90例T2DM患者纳入研究组,根据是否合并MS将其分为T2DM~MS组(n=71)、T2DM未合并MS组(n=19)。将同期于广西医科大学第二附属医院进行体检的90名健康者纳入对照组。检测并比较研究组与对照组、T2DM~MS组与T2DM未合并MS组的糖脂代谢指标[空腹血糖、高密度脂蛋白(HDL-C)、总胆固醇、低密度脂蛋白(LDL-C)、甘油三酯]及血清CTRP9、A-FABP水平。采用Pearson相关性分析CTRP9、A-FABP与各糖脂代谢指标的相关性;采用受试者操作特征(ROC)曲线评价CTRP9、A-FABP对T2DM~MS的诊断效能。结果研究组的空腹血糖、总胆固醇、LDL-C、甘油三酯及血清A-FABP水平分别为(9.37±0.95)mmol/L、(4.38±0.45)mmol/L、(2.83±0.29)mmol/L、(1.58±0.17)mmol/L、(15.48±1.72)ng/mL,均高于对照组,研究组HDL-C及血清CTRP9水平分别为(1.23±0.14)mmol/L、(8.38±0.85)ng/mL,均低于对照组,差异均有统计学意义(P<0.05)。T2DM~MS组空腹血糖、总胆固醇、LDL-C、甘油三酯及血清A-FABP水平分别为(10.26±1.32)mmol/L、(4.51±0.47)mmol/L、(3.15±0.33)mmol/L、(1.74±0.20)mmol/L、(18.21±2.06)ng/mL,均高于T2DM未合并MS组,T2DM~MS组HDL-C及血清CTRP9水平分别为(1.12±0.13)mmol/L、(7.26±0.75)ng/mL,均低于T2DM未合并MS组,差异均有统计学意义(P<0.05)。经Pearson相关分析,血清CTRP9水平与空腹血糖、总胆固醇、LDL-C、甘油三酯均呈负相关(r=-0.902、-0.780、-0.745、-0.753;均P<0.05),与HDL-C呈正相关(r=0.827,P<0.05);血清A-FABP水平与空腹血糖、总胆固醇、LDL-C、甘油三酯均呈正相关(r=0.843、0.812、0.839、0.722;均P<0.05),与HDL-C呈负相关(r=-0.768,P<0.05)。经ROC曲线分析,血清CTRP9联合A-FABP对T2DM~MS的诊断效能高于两者单独诊断。结论T2DM~MS患者血清CTRP9水平低表达,A-FABP水平高表达,血清CTRP9、A-FABP水平与糖脂代谢指标密切相关。血清CTRP9联合A-FABP可提高T2DM~MS的诊断效能,监测血清CTRP9、A-FABP水平有助于预测T2DM~MS的发生。

妊娠期糖尿病孕妇血清PPARγ、FABP4、CST与胰岛素抵抗的关系及对妊娠结局的影响

目的探讨妊娠期糖尿病(GDM)孕妇过氧化物酶体增殖物激活受体γ(PPARγ)、脂肪酸结合蛋白4(FABP4)及皮质抑素(CST)的表达与胰岛素抵抗的关系及对妊娠结局的影响,以期为GDM孕妇的临床干预提供参考。方法选取2021年9月—2023年9月陕西省人民医院收治的GDM孕妇83例作为观察组,另选取同期进行孕检且结果正常的健康孕妇67例作为对照组。统计GDM孕妇的妊娠结局,对比GDM孕妇和健康孕妇孕早期、孕中期及孕晚期血清PPARγ、FABP4、CST水平及胰岛素抵抗指数(HOMA-IR),采用Pearson相关分析PPARγ、FABP4、CST与HOMA-IR的关系,并分析影响GDM孕妇妊娠结局的相关因素。结果观察组孕妇孕早期、孕中期及孕晚期血清FABP4及HOMA-IR水平均高于对照组,血清PPARγ、CST水平均低于对照组,差异均有统计学意义(P<0.05)。Pearson相关分析结果显示,GDM孕妇血清FABP4水平与HOMA-IR呈正相关(r=0.754,P<0.001),血清PPARγ和CST水平与HOMA-IR呈负相关(r=-0.679、-0.836,P<0.001)。观察组孕妇正常妊娠69例,不良妊娠14例;对照组孕妇正常妊娠66例,不良妊娠1例;观察组孕妇不良妊娠结局发生率为16.87%(14/83),高于对照组的1.49%(1/67),差异有统计学意义(χ^(2)=9.737,P=0.002)。不同妊娠结局GDM孕妇的年龄、孕周及高血压病史比例比较,差异均无统计学意义(P>0.05);不良妊娠GDM孕妇身体质量指数(BMI)>25 kg/m^(2)、糖尿病家族史比例及血清FABP4、HOMA-IR水平均高于正常妊娠GDM孕妇,血清PPARγ及CST水平均低于正常妊娠GDM孕妇,差异均有统计学意义(P<0.05)。logistic回归分析结果显示,BMI、糖尿病家族史及血清PPARγ、CST、FABP4、HOMA-IR水平是GDM孕妇发生不良妊娠结局的影响因素(P<0.05)。结论GDM孕妇血清FABP4、PPARγ和CST表达异常,并与胰岛素抵抗、妊娠结局密切相关。临床应针对GDM孕妇给予饮食、药物等有效干预,以控制血糖变化,从而改善妊娠结局。

视网膜静脉阻塞患者血清FABP4,VWF和LCN-2水平表达与继发黄斑水肿程度及预后的关系研究

目的 探究视网膜静脉阻塞(retinal vein obstruction,RVO)患者血清脂肪细胞型脂肪酸结合蛋白(fatty acid-binding protein 4,FABP4)、血管性假血友病因子(von willebrand factor,VWF)、脂质运载蛋白2(lipocalin-2,LCN-2)水平表达与继发黄斑水肿(macular edema,ME)程度及预后的关系研究。方法 选取2021年1月~2023年8月来西北大学附属第一医院治疗的98例确诊的RVO继发ME患者为观察组,根据黄斑水肿程度分为重度组(n=46)、中度组(n=32)和轻度组(n=20),根据预后情况分为预后不良组(n=36)和预后良好组(n=62);另选取98例单纯RVO患者为对照组。比较各组血清FABP4,VWF,LCN-2水平;多因素Logistic回归分析RVO继发ME患者发生预后不良的影响因素;ROC曲线分析血清FABP4,VWF和LCN-2水平对RVO继发ME患者发生预后不良的预测价值。结果 与对照组相比,观察组血清FABP4(35.24±4.43 ng/ml vs 23.19±3.69 ng/ml),VWF(2.67±0.67 ng/ml vs1.48±0.38 ng/ml),LCN-2(112.53±12.74 mg/L vs 85.49±9.86 mg/L)水平明显升高,差异具有统计学意义(t=20.690,15.294,16.616,均P<0.05);随病情逐渐发展,轻、中、重度组血清FABP4(33.38±4.29 ng/ml,35.79±4.49 ng/ml,38.64±4.65 ng/ml),VWF(2.36±0.59 ng/ml,2.72±0.66 ng/ml,3.29±0.87 ng/ml),LCN-2(105.84±12.24 mg/L,114.61±12.88 mg/L,124.59±13.69 mg/L)水平逐渐升高,差异具有统计学意义(F=10.194,13.294,15.703,均P<0.05);与预后良好组相比,预后不良组血清FABP4(39.64±4.59 ng/ml vs 32.69±4.34 ng/ml),VWF(3.26±0.87ng/ml vs 2.33±0.55 ng/ml),LCN-2(124.56±13.42 mg/L vs 105.54±12.34 mg/L)水平明显升高,差异具有统计学意义(t=7.482,6.487,7.122,均P<0.05));血清FABP4(OR=2.236,95%CI:1.109~4.510),VWF(OR=2.069,95%CI:1.044~4.100),LCN-2(OR=1.875,95%CI:1.015~3.463)为RVO继发ME患者发生预后不良的独立危险因素(均P<0.05);血清FABP4,VWF,LCN-2水平预测患者发生预后不良的AUC(95%CI)分别为0.817(0.726~0.888),0.791(0.697~0.867)和0.798(0.705~0.872),三者联合预测的AUC为0.932(0.863~0.973),三者联合预测优于各因子单独预测(Z=2.034,2.375,2.385,P=0.042,0.018,0.017)。结论 RVO继发ME患者血清FABP4,VWF和LCN-2水平均上调,且均为患者发生预后不良的独立危险因素,三者联合检测对RVO继发ME患者发生预后不良具有更高的预测价值。

克罗恩病患者血清CCL11及I-FABP的表达水平与疾病活动指数的相关性研究

目的探究克罗恩病(CD)患者血清嗜酸性粒细胞趋化因子(CCL11)及肠脂肪酸结合蛋白(I-FABP)水平表达与疾病活动指数的相关性。方法选取2021年2月至2023年2月于上海市杨浦区中心医院就诊的98例CD患者进行研究(CD组),根据疾病活动指数(CDAI)评分将患者分为缓解期21例、轻度活动期31例、中度活动期28例和重度活动期18例,另选取同期健康者100例作为对照组,采用酶联免疫吸附法检测血清CCL11、I-FABP水平,采用Spearman法分析血清CCL11、I-FABP水平与CDAI评分的相关性,采用受试者工作特征曲线(ROC)分析血清CCL11、I-FABP水平对CD患者疾病活动度的评估价值。结果CD组患者的血清CCL11、I-FABP水平分别为(51.33±7.14)pg/mL、(64.85±11.56)ng/mL,明显高于对照组的(28.56±6.61)pg/mL、(31.38±10.35)ng/mL,差异均有统计学意义(P<0.05);缓解期、轻度、中度、重度活动期CD患者血清CCL11水平分别为(31.47±7.02)pg/mL、(45.52±7.08)pg/mL、(57.83±7.12)pg/mL、(74.41±7.43)pg/mL,I-FABP水平分别为(48.13±10.79)ng/mL、(59.97±11.32)ng/mL、(70.76±11.75)ng/mL、(83.58±12.58)ng/mL,缓解期、轻度活动期、中度活动期、重度活动期CD患者血清CCL11、I-FABP水平依次升高,差异均有统计学意义(P<0.05)。Spearman相关性分析结果显示,血清CCL11、I-FABP水平均与CDAI评分呈正相关(r=0.834、0.620,P<0.01);ROC分析结果显示,血清CCL11、I-FABP水平评估CD患者疾病活动度的AUC分别为0.882、0.889,敏感性为81.82%、80.52%,特异性为85.71%、85.71%。两者联合评估疾病活动度的AUC为0.938,显著高于单项检测(P<0.05),联合检测的敏感性和特异性为93.51%、85.71%。结论CD患者血清CCL11、I-FABP水平升高,与疾病活动指数密切相关,且两者联合评估CD患者疾病活动度具有较高效能。

血清H-FABP、GDF-15表达对STEMI患者PCI后不良心血管事件的预测价值

目的:探究血清心型脂肪酸结合蛋白(heart-type fatty acid binding protein,H-FABP)、生长分化因子-15(growth and differentiation factor-15,GDF-15)表达对ST段抬高型心肌梗死(ST-segment elevation myocardial infarction,STEMI)患者经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)后不良心血管事件发生的预测价值。方法:采用前瞻性研究,选择2020年6月—2023年6月于赣州市人民医院接受PCI的140例STEMI患者作为研究对象,术前检测患者血清H-FABP、GDF-15,行PCI,术后随访3个月,统计患者术后不良心血管事件发生情况,分析血清H-FABP、GDF-15与STEMI患者术后不良心血管事件发生的关系,同时绘制受试者工作特征(receiver operating characteristic,ROC)曲线,探究血清H-FABP、GDF-15对STEMI患者PCI后不良心血管事件发生的预测价值。结果:随访3个月期间,140例患者均无脱落病例;随访期间,140例STEMI患者PCI后发生不良心血管事件占比为23.57%(33/140),未发生不良心血管事件占比为76.43%(107/140)。两组心肌梗死面积、高血压、既往吸烟史比较,差异均有统计学意义(P<0.05);两组性别、年龄、病变支数、既往饮酒史、肌红蛋白(myoglobin,Myo)、心肌肌钙蛋白I(cardiac troponin I,cTnI)、肌酸激酶同工酶(creatine kinase-MB,CK-MB)、心室舒张末期内径(left ventricular end diastolic dimension,LVEDD)比较,差异均无统计学意义(P>0.05)。发生组血清H-FABP、GDF-15均高于未发生组,差异均有统计学意义(P<0.05)。点二列相关性分析显示,血清H-FABP、GDF-15与STEMI患者PCI后不良心血管事件发生呈正相关(r>0,P<0.05)。ROC曲线结果显示,血清H-FABP、GDF-15单独预测的AUC>0.7,联合预测的AUC>0.8,联合预测价值更高。结论:STEMI患者PCI前血清H-FABP、GDF-15水平越高,术后不良心血管事件发生风险越大,且临床可以将血清H-FABP、GDF-15作为STEMI患者PCI后不良心血管事件发生的有效预测指标。

血清肠型脂肪酸结合蛋白(I-FABP)在慢加急性肝衰竭发生发展中的预测价值

目的探讨血清肠型脂肪酸结合蛋白(I-FABP)对慢加急性肝衰竭(ACLF)发生发展的预测作用。方法回顾性分析2020年9月—2023年3月延边大学附属医院收治的168例肝硬化失代偿患者的临床资料,观察入院合并ACLF的患者情况和随访6个月新发ACLF事件。采用ELISA法测定患者入院血清I-FABP水平。非正态分布计量资料两组间比较采用MannWhitney U检验,多组间比较采用Kruskal-Wallis H秩和检验。计数资料组间比较采用χ^(2)检验。趋势性分析采用JonckheereTerpstra检验。采用Spearman相关分析两变量间相关性。多变量Cox回归法分析随访期间新发ACLF的影响因素。KaplanMeier曲线分析不同组间ACLF发生情况,并采用Log-rank检验评估差异。采用受试者工作特征曲线(ROC曲线)和曲线下面积评估I-FABP对ACLF发生、发展的预测性能。结果入组168例患者中43例合并ACLF,125例无ACLF的患者在随访期间新发ACLF19例。纳入时合并ACLF患者的I-FABP水平高于无ACLF者,差异有统计学意义(Z=4.359,P<0.001)。新发ACLF患者的I-FABP水平均高于未发生ACLF者,差异有统计学意义(Z=3.414,P<0.001)。I-FABP随ACLF分级增加而升高(H=17.385,P<0.001,P趋势<0.001)。多因素分析显示I-FABP与随访期间新发ACLF独立相关(HR=2.138,95%CI:1.297~3.525,P=0.003),且I-FABP三分位数显示出良好的区分能力(χ^(2)=12.16,P<0.001)。ROC曲线显示I-FABP对ACLF发生和发展具有较好的预测效能,ROC曲线下面积分别为0.854(95%CI:0.791~0.903)和0.747(95%CI:0.661~0.820),最佳截断值分别为2.07µg/L和1.86µg/L。结论I-FABP是预测ACLF发生和发展的生物标志物,有助于临床识别高危患者,改善临床管理。

子宫内膜癌组织LAMB3、FABP6表达及其预后价值

目的探讨层黏连蛋白亚基β3(LAMB3)、脂肪酸结合蛋白6(FABP6)在子宫内膜癌组织中的表达及预后价值。方法以本院接受手术治疗的113例子宫内膜癌患者术中收集的子宫内膜癌组织及其癌旁组织为研究样本。检测LAMB3、FABP6在组织中的表达情况;分析LAMB3和FABP6与患者预后的关系;分析影响子宫内膜癌患者预后的危险因素。结果子宫内膜癌组织中LAMB3、FABP6表达水平高于癌旁组织(P<0.05)。子宫内膜癌组织中LAMB3与FABP6表达具有正相关关系(P<0.05)。LAMB3低表达组的生存率高于高表达组(P<0.05),FABP6低表达组的生存率高于高表达组(P<0.05);FIGO分期为Ⅲ期、肌层浸润深度≥1/2、淋巴结转移、低分化、POLE无突变型、LAMB3高表达及FABP6高表达是子宫内膜癌患者3年内死亡的危险因素(P<0.05)。结论LAMB3、FABP6在子宫内膜癌组织中异常高表达,两者与患者临床病理特征及预后密切相关。

β-珠蛋白生成障碍性贫血患者血清FABP4,FGF19水平表达及与预后的关系

目的研究β-珠蛋白生成障碍性贫血(beta-thalassaemia,β-TM)患者血清脂肪酸结合蛋白4(fatty acidbindingprotein 4,FABP4)、纤维细胞生长因子19(fibroblast growth factor 19,FGF19)表达及其与预后的关系。方法选取2018年1月~2020年8月重庆大学附属黔江医院诊治的112例β-珠蛋白生成障碍性贫血患者为病例组,选取同期体检的60例健康人为对照组。采用酶联免疫吸附实验(ELISA)检测血清FABP4和FGF19水平。Logistic回归模型分析β-珠蛋白生成障碍性贫血患者预后影响因素。受试者工作特征(ROC)曲线分析血清FABP4和FGF19对β-珠蛋白生成障碍性贫血患者预后的预测价值。结果病例组患者血清FABP4(67.13±11.35μg/L)水平高于对照组(22.01±4.16μg/L),血清FGF19(104.24±21.46 ng/L)水平低于对照组(218.01±36.79 ng/L),差异均具有统计学意义(t=29.708,25.620,均P<0.05)。轻型组、中间型组及重型组患者血清FABP4水平(54.20±12.63μg/L,66.83±10.5μg/L,79.72±11.05μg/L)依次升高,而FGF19水平(122.53±22.36 ng/L,103.16±20.37 ng/L,86.53±18.14 ng/L)依次降低,差异具有统计学意义(F=39.701,24.231,均P<0.05)。相比于生存组,死亡组患者血清FGF19(62.80±22.09 ng/L vs 110.16±20.69 ng/L),血红蛋白、杂合子基因型比例(βCD17/βN,βCD41-42/βN)较低,而血清FABP4(116.69±12.30 ng/L vs 60.05±10.17 ng/L),铁蛋白及心脏增大比例较高,差异具有统计学意义(t/χ^(2)=4.436~18.981,均P<0.05)。FGF19(OR=0.634,95%CI:0.451~0.891)是β-珠蛋白生成障碍性贫血患者预后的独立保护因素(P<0.001),血清FABP4(OR=1.840,95%CI:1.193~2.838)为预后独立危险因素(P<0.001)。血清FABP4,FGF19联合对β-珠蛋白生成障碍性贫血患者预后评估的曲线下面积(95%CI)为0.897(0.853~0.951),大于单指标检测0.842(0.801~0.879)和0.814(0.762~0.858),差异具有统计学意义(Z=4.864,5.270,P=0.002,0.001)。结论β-珠蛋白生成障碍性贫血患者血清FABP4升高,FGF19降低。血清FABP4,FGF19联合检测对β-珠蛋白生成障碍性贫血患者预后具有较高的预测价值。

尿肝型脂肪酸结合蛋白(L-FABP)对慢加急性肝衰竭短期预后的预测价值

目的探讨肝型脂肪酸结合蛋白(L-FABP)对慢加急性肝衰竭(ACLF)患者严重程度及短期预后的预测价值。方法研究对象149例来自于一个评估ACLF患者血小板功能的前瞻性、多中心队列,根据入院28天预后分为生存组(n=97)与死亡组(n=52)。分析患者的性别、年龄、病因以及入院后24 h内的血常规、生化指标、器官衰竭情况并检测尿液及血液中LFABP水平。正态分布的计量资料2组间比较使用成组t检验;非正态资料分布的计量资料2组间比较采用Mann-Whitney U检验;计数资料2组间比较采用χ^(2)检验。Spearman相关性检验评估尿L-FABP与肝衰竭相关指标的相关性。绘制受试者工作特征曲线(ROC曲线)评价CLIF-OFs、MELD评分和尿L-FABP对于ACLF患者短期预后的预测价值;通过Kaplan-Meier分析尿L-FABP高水平组与低水平组患者短期死亡情况;采用Cox风险比例模型分析各因素对ACLF短期预后的影响。结果两组患者在白细胞计数、血清TBil、INR、CLIF-OFs、MELD评分和尿L-FABP水平;脑衰竭、肝衰竭、凝血衰竭、肾脏衰竭、呼吸衰竭的比例方面差异均有统计学意义(P值均<0.05)。相关性分析结果显示,尿L-FABP与血清TBil呈显著正相关(r=0.225,P=0.006)。尿L-FABP水平预测28天预后的ROC曲线下面积(AUC)为0.804(95%CI:0.729~0.865,P<0.001),截断值为4.779µg/dL(敏感度为73.08%,特异度为73.91%,约登指数为0.4699)。Kaplan-Meier生存分析发现,相比于尿L-FABP低水平组(尿L-FABP≤4.779µg/dL),尿L-FABP高水平组(尿L-FABP>4.779µg/dL)28天生存率显著降低(P<0.001)。Cox风险比例模型分析发现,血清TBil(HR=1.003,95%CI:1.001~1.004)、CLIF-OFs(HR=2.283,95%CI:1.814~2.873)和高尿L-FABP水平(HR=4.568,95%CI:2.424~8.608)为ACLF短期预后的独立危险因素(P值均<0.05)。结论高尿L-FABP水平可作为ACLF短期预后的临床预测指标,需扩大样本量进一步验证其预测价值。

FABP5在肿瘤中作用及机制的研究进展

脂肪酸结合蛋白5(fatty acid binding protein 5,FABP5)是脂肪酸结合蛋白家族之一,在调控脂肪酸的摄取、运输和代谢中发挥重要作用。近年来多项研究证实,FABP5在多种肿瘤中高表达,其参与了肿瘤的增殖、转移以及诱导免疫逃逸等多种肿瘤生物学过程。该文综述了FABP5在肿瘤中的最新研究进展,旨在讨论FABP5在肿瘤中的作用及机制,为肿瘤相关研究提供新思路,同时为肿瘤新靶点的开发提供更多理论依据。

FABP3基因对动物肉质性状的影响研究进展

随着社会经济的发展,人们对于优质肉类产品的需求不断提高。动物肌内脂肪含量是影响肉品质量的重要指标之一,受到多个基因的调控。心脏型脂肪酸结合蛋白(H-FABP),又称FABP3,是一种在心肌细胞中发现的新型小胞质蛋白,主要存在于心肌和骨骼肌中,在脂肪酸的摄取、转运及代谢调节中发挥重要作用。本文就FABP3基因对肉质性状的影响研究进展进行综述,以期为动物肉质的遗传改良提供理论依据。

基于无缝管理理念的MDT模式对CHF患者的临床疗效及其H-FABP、cTnI水平与心功能的关系研究

目的:探讨无缝管理理念下的多学科协作(MDT)模式对慢性心力衰竭(CHF)患者的临床疗效,并分析心型脂肪酸结合蛋白(H-FABP)、心肌肌钙蛋白I(cTnI)水平与心功能指标的相关性。方法:纳入2020年11月-2021年11月本院收治的222例CHF患者,根据随机数字表法分为对照组(111例,采用MDT模式干预)和实验组(111例,采用无缝管理理念联合MDT模式干预)。干预一个月后,采用心力衰竭自我管理量表评价两组患者临床疗效,并比较两组干预前后明尼苏达心力衰竭生活质量问卷(MLHFQ)评分、H-FABP、cTnI水平及心功能指标,采用Pearson相关分析法分析H-FABP、cTnI水平与心功能指标的相关性。结果:干预一个月后,与对照组比较,实验组心力衰竭自我管理量表得分[(50.04±6.08)分比(72.07±5.65)分]、左室射血分数(LVEF)[(36.23±3.68)%比(43.42±3.36)%]、6min步行距离(6MWD)[(228.35±28.78)m比(337.29±32.31)m]均显著增加,MLHFQ评分[(40.14±3.25)分比(33.05±4.61)分]、H-FABP[(5.97±0.57)ng/ml比(2.77±0.59)ng/ml]、cTnI[(3.34±0.33)ng/ml比(2.45±0.61)ng/ml]水平均显著降低(P均<0.001)。CHF患者H-FABP、cTnI水平随心功能分级提升呈显著上升趋势(P均<0.001)。Pearson相关分析显示,H-FABP、cTnI与LVEF、6MWD呈显著负相关(r=-0.745~-0.676,P均<0.001),与BNP水平呈显著正相关(r=0.705、0.668,P均<0.001)。结论:无缝管理理念的MDT模式应用于CHF的临床治疗,能显著改善患者生活质量及心功能,联合H-FABP、cTnI检测对指导CHF患者预后评估及心功能监测具有重要临床意义。